Kopran Limited
261.30
INR
-2.70
(-1.02%)
ISIN
INE082A01010
Return %
Stock
S&P 500
1Y
54.20
14.20
3Y
19.70
81.12
5Y
28.03
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Surendra Shrikrishna Somani
- Full Time Employees
- 1,156
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Parijat House Mumbai MA India 400018
- IPO Date
- Nov 17, 1992
- Website
- kopran.com
- Similar Companies
- Business
- Kopran Limited operates as an international pharmaceutical company specializing in the manufacture and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company’s core product portfolio includes over 30 APIs across various therapeutic segments such as antibiotics (penicillins, macrolides, cephalosporins, carbapenems), antidiabetics, cardiovascular drugs, anticoagulants, neuromodulators, and oncology products. In addition, Kopran produces finished dosage forms in diverse therapeutic categories including gastroenterology, anthelmintics, central nervous system, pain management, anti-allergics, anti-asthmatics, anti-infectives, anti-protozoals, erectile dysfunction, and respiratory drugs. The company also offers contract development and manufacturing services, supporting pharmaceutical companies globally. Kopran operates two WHO GMP approved manufacturing facilities, including a wholly owned subsidiary, Kopran Research Laboratories Limited, which has notable API manufacturing units in India. Founded in 1958 and headquartered in Mumbai, India, Kopran has recently undergone significant strategic and operational developments. The company has approved a merger with a promoter group company to consolidate operations and enhance shareholding structure. In the past 1-2 years, Kopran has experienced financial challenges, including a sharp decline in revenue and profitability, with Q2 FY26 showing substantial losses and margin pressures attributed to operational inefficiencies. Despite business challenges, Kopran continues to invest in product innovation such as the development and patenting of Nitrosamine and genotoxic impurity free Nitroxoline, exemplifying its commitment to quality and innovation in APIs. The company maintains a focus on strengthening its supply chain and expanding its product offerings, aiming to stabilize revenue and regain profitability. Kopran’s business segments cover pharmaceutical formulations, API manufacturing, and contract manufacturing underpinned by advanced reaction capabilities such as chiral synthesis, high-pressure hydrogenation, enzymatic reactions, and cryogenic processes. The company targets generic drug manufacturers and pharmaceutical companies worldwide, catering to regulated markets. While facing recent financial headwinds, Kopran is positioned as a key player in the Indian pharmaceutical landscape with a strong historical presence and ongoing initiatives aimed at operational turnaround and growth. Kopran Limited trades on the National Stock Exchange of India under the ticker KOPRAN and continues to report compliance with regulatory standards including regular business responsibility and sustainability disclosures.